Novo Nordisk has revealed that its drug Ozempic (semaglutide) has received approval from the European Commission (EC) as a monotherapy for the treatment of type 2 diabetes in patients for whom metformin is inappropriate.
The EC’s decision was based on data which demonstrates “the superior and sustained reductions in HbA1c and body weight” associated with the use of Ozempic compared to similar treatments, in addition to “cardiovascular benefits and the statistically significant reduction in diabetic nephropathy”.
